Invention Grant
US09028833B2 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
有权
免疫缀合物的抗体和SN-38的用量可以提高功效和降低毒性
- Patent Title: Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
- Patent Title (中): 免疫缀合物的抗体和SN-38的用量可以提高功效和降低毒性
-
Application No.: US13948732Application Date: 2013-07-23
-
Publication No.: US09028833B2Publication Date: 2015-05-12
- Inventor: Serengulam V. Govindan , David M. Goldenberg
- Applicant: Immunomedics, Inc.
- Applicant Address: US NJ Morris Plains
- Assignee: Immunomedics, Inc.
- Current Assignee: Immunomedics, Inc.
- Current Assignee Address: US NJ Morris Plains
- Agent Richard A. Nakashima
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/00 ; A61K47/48 ; A61K31/337 ; A61K31/4184 ; A61K31/4375 ; A61K31/513 ; A61K31/675 ; A61K31/7088 ; A61K31/713 ; A61K33/24 ; A61K38/00 ; A61K38/14 ; A61K38/19 ; A61K45/06 ; A61K48/00 ; A61K51/10 ; A61N5/00 ; A61K31/454 ; A61N5/10 ; C07K16/28 ; C07K16/30
Abstract:
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
Public/Granted literature
- US20140170063A1 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity Public/Granted day:2014-06-19
Information query
